May 15, 2026 Last checked 2026-05-16 20:00 UTC Publication Research
Claim boundary.retrospective uncontrolled multimodal clinic-regimen signal only; not randomized proof, not classic psychedelic efficacy evidence, not approval/label/access/reimbursement, not medical advice, and not generalizable safety proof.
Last checked: 2026-05-16 20:00 UTC. PubMed abstract describes a Journal of Affective Disorders retrospective cohort of 233 TRD patients receiving esketamine plus dexmedetomidine patient-controlled sleep (PCSL), with follow-up at 1, 3, and 6 months. Abstract reports HAMD/PSQI decreases and response rates of 62.00%, 59.73%, and 58.49%, with no serious adverse events observed during follow-up. Claim boundary: retrospective uncontrolled multimodal clinic-regimen signal only; not randomized proof, not classic psychedelic efficacy evidence, not approval/label/access/reimbursement, not medical advice, and not generalizable safety proof.
Source/tracker note
PubMed PMID 41621446 / DOI 10.1016/j.jad.2026.121311. Abstract: retrospective inclusion of 233 TRD patients; HAMD and PSQI assessed at 1, 3, and 6 months after first esketamine infusion; PCSL and additional esketamine recorded; HAMD/PSQI scores decreased significantly; response rates 62.00%, 59.73%, 58.49%; no serious adverse events observed during follow-up.
May 15, 2026 Last checked 2026-05-16 UTC Publication Research
Claim boundary.observational real-world evidence synthesis only; not new approval, label expansion, reimbursement/access finding, proof of comparative efficacy, or broad safety guarantee. Abstract itself cautions that observational evidence and absence of control groups mean effect sizes should be interpreted with caution.
PubMed PMID 41616859 is a systematic review/meta-analysis of nine observational real-world studies of intranasal esketamine for treatment-resistant depression; abstract reports symptom reduction/remission patterns and pooled adverse-event/dissociation estimates.
Source/tracker note
Last checked 2026-05-16 UTC. Claim boundary: observational real-world evidence synthesis only; not new approval, label expansion, reimbursement/access finding, proof of comparative efficacy, or broad safety guarantee. Abstract itself cautions that observational evidence and absence of control groups mean effect sizes should be interpreted with caution.
May 14, 2026 Last checked 2026-05-16 16:00 UTC Publication Research
Claim boundary.observational clinic/precision-medicine correlate; not psychedelic efficacy evidence, not randomized proof, not approval/access/medical advice.
Last checked: 2026-05-16 16:00 UTC. Journal of Affective Disorders abstract reports a MGH Ketamine Clinic observational/network-analysis study of 447 TRD patients receiving acute-phase IV ketamine or intranasal esketamine. Abstract says pre-treatment symptom-network density was higher in non-responders than responders and frames baseline network density as a potential correlate of ketamine outcomes. Claim boundary: observational clinic/precision-medicine correlate; not psychedelic efficacy evidence, not randomized proof, not approval/access/medical advice.
Source/tracker note
Abstract: “447 patients receiving acute-phase intravenous ketamine or intranasal esketamine at the MGH Ketamine Clinic were included.” “Pre-treatment network density was significantly higher in non-responders ... compared to responders ...” “Pre-treatment network density serves as a potential correlate of treatment outcomes of ketamine for TRD.”
May 1, 2026 Last checked 2026-05-16 16:00 UTC Publication Research
Claim boundary.narrative/public-health signal, not clinical efficacy evidence, not US prevalence, not medical advice, and distinct from regulated ketamine/esketamine treatment contexts.
Last checked: 2026-05-16 16:00 UTC. British Journal of General Practice narrative review/public-health article describes rising UK ketamine misuse among young people; PubMed lists May 2026. Abstract says deaths increased six-fold over the past decade, ketamine is now the fifth most commonly used drug among young people, and urinary/abdominal presentations can mask dependence or ketamine-related harm. Claim boundary: narrative/public-health signal, not clinical efficacy evidence, not US prevalence, not medical advice, and distinct from regulated ketamine/esketamine treatment contexts.
Source/tracker note
Abstract: “Ketamine ... has become one of the fastest growing substances of misuse in the UK, with deaths increasing six-fold over the past decade.” “It is now the fifth most commonly used drug among young people...” “presentations frequently occur under the guise of urinary or abdominal symptoms.”